IMR Press / FBL / Volume 23 / Issue 11 / DOI: 10.2741/4692

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Epigenetic regulation of genes involved in the reverse cholesterol transport through interaction with miRNAs

Show Less
1 University of Lorraine, School of Pharmacy, 5 rue Albert Lebrun, 54000 Nancy, France
2 University of Lorraine, Nanomateriaux et Sante, Institut Jean-Lamour, 2 allee Andre Guinier, 54000 Nancy, France
3 State University of New York, Downstate Medical Center, Department of Medicine, 450 Clarkson Ave, Brooklyn, New York 11203, USA
Front. Biosci. (Landmark Ed) 2018, 23(11), 2090–2105; https://doi.org/10.2741/4692
Published: 1 June 2018
Abstract

microRNAs (miRNAs) are a group of small non-coding RNA molecules known to regulate target genes at the post-transcriptional level. miRNAs are implicated in the regulation of multiple pathophysiological processes including dyslipidemia, a major risk factor for atherosclerosis. Emerging evidence suggests that miRNAs act as a novel class of epigenetic regulators of high-density lipoproteins cholesterol (HDL-C) from synthesis to clearance contributing remarkably to the pathogenesis of atherosclerosis. Accumulating studies have revealed that miRNAs such as miR-33, miR-27, miR-144, miR-758 and miR-20 are involved in the post-transcriptional control of ABCA1, ABCG1 and SCARB1 genes regulatory network of the reverse cholesterol transport (RCT). These miRNAs have been shown to be central players in the impairment of RCT pathway leading to the development of atherosclerosis. In this article, we present most recent understanding of involvement of relevant miRNAs in different steps of HDL metabolism and RCT pathway. We also discuss some of the actual limitations to the promise of these miRNAs and perspectives on their translation to clinical settings.

Keywords
miRNA
ABCA1
HDL
SR-BI
Reverse cholesterol transport
Review
Share
Back to top